These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 26186480)

  • 1. Trivalent ligands for CXCR4 bearing polyproline linkers show specific recognition for cells with increased CXCR4 expression.
    Nomura W; Koseki T; Ohashi N; Mizuguchi T; Tamamura H
    Org Biomol Chem; 2015 Aug; 13(32):8734-9. PubMed ID: 26186480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bivalent 14-mer peptide ligands of CXCR4 with polyproline linkers with anti-chemotactic activity against Jurkat cells.
    Tanaka T; Aoki T; Nomura W; Tamamura H
    J Pept Sci; 2017 Jul; 23(7-8):574-580. PubMed ID: 28078743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bivalent ligands of CXCR4 with rigid linkers for elucidation of the dimerization state in cells.
    Tanaka T; Nomura W; Narumi T; Masuda A; Tamamura H
    J Am Chem Soc; 2010 Nov; 132(45):15899-901. PubMed ID: 20973474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploration of labeling by near infrared dyes of the polyproline linker for bivalent-type CXCR4 ligands.
    Nomura W; Aikawa H; Taketomi S; Tanabe M; Mizuguchi T; Tamamura H
    Bioorg Med Chem; 2015 Nov; 23(21):6967-73. PubMed ID: 26453409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High affinity CXCR4 inhibitors generated by linking low affinity peptides.
    Zhang C; Huang LS; Zhu R; Meng Q; Zhu S; Xu Y; Zhang H; Fang X; Zhang X; Zhou J; Schooley RT; Yang X; Huang Z; An J
    Eur J Med Chem; 2019 Jun; 172():174-185. PubMed ID: 30978562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detecting Cell Surface Expression of the G Protein-Coupled Receptor CXCR4.
    Nevins AM; Marchese A
    Methods Mol Biol; 2018; 1722():151-164. PubMed ID: 29264804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of novel non-peptide CXCR4 antagonists by ligand-based design approach.
    Ueda S; Kato M; Inuki S; Ohno H; Evans B; Wang ZX; Peiper SC; Izumi K; Kodama E; Matsuoka M; Nagasawa H; Oishi S; Fujii N
    Bioorg Med Chem Lett; 2008 Jul; 18(14):4124-9. PubMed ID: 18539453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and application of fluorescein- and biotin-labeled molecular probes for the chemokine receptor CXCR4.
    Oishi S; Masuda R; Evans B; Ueda S; Goto Y; Ohno H; Hirasawa A; Tsujimoto G; Wang Z; Peiper SC; Naito T; Kodama E; Matsuoka M; Fujii N
    Chembiochem; 2008 May; 9(7):1154-8. PubMed ID: 18412193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ligand stabilization of CXCR4/delta-opioid receptor heterodimers reveals a mechanism for immune response regulation.
    Pello OM; Martínez-Muñoz L; Parrillas V; Serrano A; Rodríguez-Frade JM; Toro MJ; Lucas P; Monterrubio M; Martínez-A C; Mellado M
    Eur J Immunol; 2008 Feb; 38(2):537-49. PubMed ID: 18200497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of EGFR Activation by Bivalent Ligands Based on a Cyclic Peptide Mimicking the Dimerization Arm Structure of EGFR.
    Toyama K; Kobayakawa T; Nomura W; Tamamura H
    Chem Pharm Bull (Tokyo); 2018; 66(11):1083-1089. PubMed ID: 30381661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and biological characterization of novel PEG-linked dimeric modulators for CXCR4.
    Yang Y; Gao M; Zhang Q; Zhang C; Yang X; Huang Z; An J
    Bioorg Med Chem; 2016 Nov; 24(21):5393-5399. PubMed ID: 27658790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress toward rationally designed small-molecule peptide and peptidomimetic CXCR4 antagonists.
    Våbenø J; Haug BE; Rosenkilde MM
    Future Med Chem; 2015; 7(10):1261-83. PubMed ID: 26144264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a receptor-targeted gene delivery system using CXCR4 ligand-conjugated cross-linking peptides.
    Egorova A; Bogacheva M; Shubina A; Baranov V; Kiselev A
    J Gene Med; 2014; 16(11-12):336-51. PubMed ID: 25382058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-Activity Relationship and Signaling of New Chimeric CXCR4 Agonists.
    Mona CE; Besserer-Offroy É; Cabana J; Lefrançois M; Boulais PE; Lefebvre MR; Leduc R; Lavigne P; Heveker N; Marsault É; Escher E
    J Med Chem; 2016 Aug; 59(16):7512-24. PubMed ID: 27434274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radionuclide-Labeled Peptides for Imaging and Treatment of CXCR4- Overexpressing Malignant Tumors.
    Liu N; Wan Q; Cheng Z; Chen Y
    Curr Top Med Chem; 2019; 19(1):17-32. PubMed ID: 30706786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Slamming the DOR on chemokine receptor signaling: heterodimerization silences ligand-occupied CXCR4 and delta-opioid receptors.
    Hereld D; Jin T
    Eur J Immunol; 2008 Feb; 38(2):334-7. PubMed ID: 18203136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluorescent CXCL12AF647 as a novel probe for nonradioactive CXCL12/CXCR4 cellular interaction studies.
    Hatse S; Princen K; Liekens S; Vermeire K; De Clercq E; Schols D
    Cytometry A; 2004 Oct; 61(2):178-88. PubMed ID: 15382150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insight into the binding mode for cyclopentapeptide antagonists of the CXCR4 receptor.
    Våbenø J; Nikiforovich GV; Marshall GR
    Chem Biol Drug Des; 2006 May; 67(5):346-54. PubMed ID: 16784459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Up-regulation of leukocyte CXCR4 expression by sulfatide: an L-selectin-dependent pathway on CD4+ T cells.
    Duchesneau P; Gallagher E; Walcheck B; Waddell TK
    Eur J Immunol; 2007 Oct; 37(10):2949-60. PubMed ID: 17853408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptide and peptidomimetic ligands for CXC chemokine receptor 4 (CXCR4).
    Oishi S; Fujii N
    Org Biomol Chem; 2012 Aug; 10(30):5720-31. PubMed ID: 22517031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.